Journal:IUCrJ:S205225251901707X

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
<hr/>
<hr/>
<b>Molecular Tour</b><br>
<b>Molecular Tour</b><br>
-
In response to environmental changes, proteins are released from cells that act as messengers, which allows cells to communicate with one another and coordinate a physiologic response. Transforming growth factor beta-1 (TGFb-1) is a protein used to communicate information about when and how cells should proliferate and is particularly important in organizing embryonic tissue development. The fundamental way our cells regulate TGFb-1 activity is with a second protein, latency-associated peptide (LAP). LAP forms a complex with TGFb-1, tethering it to the outside surface of the cell. Several pathologies including cancer progression and immune suppression are driven by an overabundance of TGFb-1.
+
In response to environmental changes, proteins are released from cells that act as messengers, which allows cells to communicate with one another and coordinate a physiologic response. Transforming growth factor beta-1 (TGFβ-1) is a protein used to communicate information about when and how cells should proliferate and is particularly important in organizing embryonic tissue development. The fundamental way our cells regulate TGFβ-1 activity is with a second protein, latency-associated peptide (LAP). LAP forms a complex with TGFβ-1, tethering it to the outside surface of the cell. Several pathologies including cancer progression and immune suppression are driven by an overabundance of TGFβ-1.
-
Because LAP binding reduces TGFb-1 activity, recombinant LAP is a promising novel therapeutic approach, however a detailed understanding of how LAP binds TGFb-1 is missing, which could reveal ways to improve the LAP-TGFb-1 interaction or develop other anti-TGFb-1 therapies. In a paper in IUCrJ, Stachowski et al. show that LAP adopts structurally distinct conformations between unbound and TGFb-1 bound states. This was revealed by comparing the X-ray crystal structure of LAP in the unbound state solved by Stachowski et al. with the crystal structure of LAP bound to TGFb-1 previously reported by Shi et al. 2011. This analysis combined with solution modelling showed that LAP transitions from an extended to compact conformation when binding TGFb-1, simulating a type of hugging motion where LAP embraces TGFb-1. Surprisingly, this conformational change includes rearranging two domains that are distant from one another and might be coordinated through the formation of an a-helix that is distant from the LAP-TGFb-1 interaction site. Together, these results provide new spatial details about the TGFb-1 binding mechanism, specifically how LAP reorients itself to develop the LAP-TGFb-1 interface. This insight is important as it provides new avenues to engineer and improve LAP as a therapeutic that are focused beyond just the interaction site.
+
Because LAP binding reduces TGFβ-1 activity, recombinant LAP is a promising novel therapeutic approach, however a detailed understanding of how LAP binds TGFβ-1 is missing, which could reveal ways to improve the LAP-TGFβ-1 interaction or develop other anti-TGFβ-1 therapies. In a paper in IUCrJ, ''Stachowski et al.'' show that LAP adopts structurally distinct conformations between unbound and TGFβ-1 bound states. This was revealed by comparing the X-ray crystal structure of LAP in the unbound state solved by Stachowski et al. with the crystal structure of LAP bound to TGFβ-1 previously reported by ''Shi et al.'' 2011. This analysis combined with solution modelling showed that LAP transitions from an extended to compact conformation when binding TGFβ-1, simulating a type of hugging motion where LAP embraces TGFβ-1. Surprisingly, this conformational change includes rearranging two domains that are distant from one another and might be coordinated through the formation of an a-helix that is distant from the LAP-TGFβ-1 interaction site. Together, these results provide new spatial details about the TGFβ-1 binding mechanism, specifically how LAP reorients itself to develop the LAP-TGFβ-1 interface. This insight is important as it provides new avenues to engineer and improve LAP as a therapeutic that are focused beyond just the interaction site.
<b>References</b><br>
<b>References</b><br>

Revision as of 08:43, 5 January 2020

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Jaime Prilusky

This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
Personal tools